Avalo Therapeutics
AVTX
7 hedge funds and large institutions have $491K invested in Avalo Therapeutics in 2017 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 1 closing their positions.
0% less ownership
Funds ownership: 0% → 0% (-0%)
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
13% less funds holding
Funds holding: 8 → 7 (-1)
29% less capital invested
Capital invested by funds: $690K → $491K (-$199K)
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$2.39K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$2.39K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VKH
Virtu KCG Holdings
New York
|
-$21.5K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$16K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$11.9K |
| 4 |
AIM
Acrospire Investment Management
Chicago,
Illinois
|
-$1K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
NMC
1
NEA Management Company
Timonium,
Maryland
| $402K | – | – | – |
|
|
2
Vanguard Group
Malvern,
Pennsylvania
| $37K | -$11.9K | -5 | -21% |
|
|
VKH
3
Virtu KCG Holdings
New York
| $30K | -$21.5K | -9 | -38% |
|
4
Commonwealth Equity Services
Waltham,
Massachusetts
| $9K | – | – | – |
|
|
5
UBS Group
Zurich,
Switzerland
| $9K | +$2.39K | +1 | +25% |
|
|
TWA
6
TCI Wealth Advisors
Tucson,
Arizona
| $2K | – | – | – |
|
|
7
BlackRock
New York
| $2K | +$2.39K | +1 | New |
|
|
8
Citadel Advisors
Miami,
Florida
| – | -$16K | -6 | Closed |
|
|
AIM
9
Acrospire Investment Management
Chicago,
Illinois
| – | -$1K | – | – |
|
AVTX Hedge Fund Activity: Q1 2017 in Review
7 of the 4,018 institutional investors tracked by Wall St. Rank reported a position in Avalo Therapeutics (AVTX) for Q1 2017, worth a combined $491K — down 29% from $690K a quarter earlier.
Fund positioning in AVTX was balanced in Q1 2017: 1 fund opened new positions, 1 closed out, 1 added to existing stakes and 2 trimmed.
The largest buyer was BlackRock, opening a new position worth an estimated $2.39K. The largest seller was Virtu KCG Holdings, cutting an estimated $21.5K.
- 7 institutional investors held Avalo Therapeutics (AVTX) as of Q1 2017, down from 8 in Q4 2016.
- Funds reported $491K of Avalo Therapeutics stock for Q1 2017, down 29% quarter-over-quarter.
- 1 fund opened new Avalo Therapeutics positions in Q1 2017 and 1 closed out, a net change of 0 holders.
- The largest Avalo Therapeutics buyer in Q1 2017 was BlackRock, an estimated $2.39K added.
- The largest Avalo Therapeutics seller in Q1 2017 was Virtu KCG Holdings, an estimated $21.5K sold.
Based on aggregated 13F filings for Q1 2017.